KEY POINTS
-
Johnson & Johnson is investing over $1 billion to build a next-generation cell therapy manufacturing facility in Montgomery County, Pennsylvania. This move will significantly expand the company’s U.S. manufacturing capabilities for advanced medicines.
-
The project will be a boost for the local economy. It is expected to create more than 4,000 construction jobs during its development phase and over 500 permanent, highly skilled biomanufacturing jobs once fully operational.
-
The facility will use cutting-edge technologies to develop transformative treatments for cancer, immune-mediated diseases, and neurological conditions. It is part of a larger $55 billion U.S. investment plan by J&J through early 2029.
Johnson & Johnson announced a major construction project in Pennsylvania. On February 18, 2026, the company unveiled plans for a new cell therapy manufacturing facility, with an investment exceeding $1 billion.
The state-of-the-art site will be located in Montgomery County and is set to become a central hub for the company’s production of advanced medicines, according to a company statement.
Advancing U.S. Manufacturing Capabilities
The investment is a key part of Johnson & Johnson’s previously announced plan to invest $55 billion in its U.S. manufacturing, research, and technology operations by early 2029. The company aims to manufacture the vast majority of its advanced medicines within the United States to meet the needs of American patients.
Shown is a rendering of the planned Johnson & Johnson new cell therapy manufacturing facility in Pennsylvania. On February 18, 2026, the company unveiled plans for an investment exceeding $1 billion to build a state-of-the-art site in Montgomery County. It is set to become a central hub for the company’s production of advanced medicines, according to the company. Image: Johnson & Johnson
The new facility will be equipped with modern technologies designed to advance the company’s portfolio of treatments for complex conditions, including cancer, immune-mediated diseases, and neurological disorders.
This focus on advanced cell therapy represents a significant step forward in the future of medicine, the company said.
What it Means for Construction
The launch of J&J’s billion-dollar facility is a potential opportunity for the construction industry in Pennsylvania and beyond. With more than 4,000 construction jobs expected during development, the project will call on a large and skilled workforce, ranging from general contractors and specialty trades to project managers and engineers.
Local suppliers and service providers are also poised to benefit, reinforcing the interconnected nature of the construction and life sciences sectors.
While project plans and specifications have yet to be released, contractors, manufacturers, and trades should stay alert for project announcements as opportunities will emerge to find, bid on, and secure work as more details become available.
Beyond job creation, this investment is set to inject new momentum into the regional economy. Projects of this scale and construction category help sharpen skills, foster innovation in construction methods, and encourage collaboration among firms.
For contractors and construction professionals, the facility signals potential robust demand ahead while contributing to a lasting legacy in Pennsylvania’s industrial landscape.
“For 140 years, Johnson & Johnson has been a leading innovator in American healthcare, and we are honored to continue advancing that legacy in Pennsylvania,” said Joaquin Duato, Chairman and Chief Executive Officer of Johnson & Johnson. He noted that the project unites scientific excellence with advanced manufacturing and strategic investment.
A Boost for Pennsylvania’s Economy
The planned new facility deepens Johnson & Johnson’s already substantial presence in the state. The company currently has ten facilities across Pennsylvania, covering over 2 million square feet and contributing an estimated $10 billion annually to the state’s economy.
Pennsylvania Governor Josh Shapiro highlighted the state’s growing reputation as a leader in life sciences and manufacturing. “That’s why companies like Johnson & Johnson are choosing to double down on their investments here in our Commonwealth - because they know we’ve got the strategy, the workforce, and the speed they need to succeed.”
Stay Connected
Stay connected with ConstructConnect News, your source for construction economy insights, market trends, and project news.
About ConstructConnect
At ConstructConnect, our software solutions provide the information construction professionals need to start every project on a solid foundation. For more than 100 years, our insights and market intelligence have empowered commercial firms, manufacturers, trade contractors, and architects to make data-driven decisions and maximize productivity.
ConstructConnect is a business unit of Roper Technologies (Nasdaq: ROP), part of the Nasdaq 100, S&P 500, and Fortune 1000.
For more information, visit constructconnect.com
